| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Common Stock | Tax liability | -$11K | -182 | -2.08% | $60.58 | 8.58K | 03 Mar 2025 | Direct | F1, F2, F3 |
| transaction | CORT | Common Stock | Award | $12.8K | +216 | +2.52% | $59.07 | 8.79K | 03 Mar 2025 | Direct | F3, F4, F5 |
| transaction | CORT | Common Stock | Award | $0 | +216 | +2.46% | $0.00 | 9.01K | 03 Mar 2025 | Direct | F3, F6 |
| transaction | CORT | Common Stock | Options Exercise | $62.1K | +4.58K | +50.83% | $13.56 | 13.6K | 03 Mar 2025 | Direct | F3 |
| transaction | CORT | Common Stock | Sale | -$278K | -4.58K | -33.7% | $60.69 | 9.01K | 03 Mar 2025 | Direct | F3, F7, F8 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Stock option (right to buy) | Award | $0 | +140K | $0.00 | 140K | 28 Feb 2025 | Common Stock | 140K | $60.58 | Direct | F9 | |
| transaction | CORT | Stock option (right to buy) | Options Exercise | $0 | -4.58K | -4.74% | $0.00 | 92K | 03 Mar 2025 | Common Stock | 4.58K | $13.56 | Direct | F10 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | These shares were withheld by the Issuer in order to satisfy certain withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. |
| F2 | The closing price on February 28, 2025 was used to calculate the withholding obligation. |
| F3 | Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| F4 | The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 3, 2025. |
| F5 | In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. |
| F6 | Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. |
| F7 | The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. |
| F8 | Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.58 to $61.055 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. |
| F9 | Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date. |
| F10 | Fully exercisable. |
Chief Accounting & Technology Officer